Vertex, Inc. Class A Common Stock (VERX) News
Latest headlines that mention VERX, newest first · each headline opens the original publisher
- Last price
- $12.77
- Day change
- +3.57%
- Next earnings
- 2026-11-02
VERX headlines
latest coverageVertex dominates cystic fibrosis and has a debt-free balance sheet, but can its pipeline restore faster growth? See why our analysts gave the stock a strong 7.3 out of 10.
AI adoption jumped to 89% as Vertex narrows full-year guidance on cloud timing.
Revenue hit $3.3 billion with guidance raised on strong newer product growth.
Vertex stock surged Monday after its competitor, Sionna Therapeutics, missed the mark for its highly anticipated cystic fibrosis treatment. The post Why Vertex Pharma Popped, As A Key Rival Plummeted 92% appeared first on Investor's Business Daily .
Vertex stock regained its footing Tuesday, rising on a strong second-quarter report and amid heightened expectations for its kidney disease treatment. The post How Vertex Regained Its Footing On A Competitor's Bullish Report appeared first on Investor's Business Daily .
There are other reasons to pay attention to Viking Therapeutics.
Also mentioned with VERX
30dHeadlines that tag both tickers
VERX news alerts
Get an alert by email or push when a new headline mentions VERX.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.